# Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma

> **NCT01281865** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 14 (actual)

## Conditions studied

- Adult Synovial Sarcoma
- Recurrent Adult Soft Tissue Sarcoma
- Stage III Adult Soft Tissue Sarcoma
- Stage IV Adult Soft Tissue Sarcoma

## Interventions

- **OTHER:** diagnostic laboratory biomarker analysis
- **DRUG:** everolimus
- **DRUG:** imatinib mesylate

## Key facts

- **NCT ID:** NCT01281865
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2014-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01281865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01281865, "Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01281865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*